KR100884685B1 - 신속 방출 활성 물질을 함유하는 초순도 플루다라 경구제제 - Google Patents
신속 방출 활성 물질을 함유하는 초순도 플루다라 경구제제 Download PDFInfo
- Publication number
- KR100884685B1 KR100884685B1 KR1020047009750A KR20047009750A KR100884685B1 KR 100884685 B1 KR100884685 B1 KR 100884685B1 KR 1020047009750 A KR1020047009750 A KR 1020047009750A KR 20047009750 A KR20047009750 A KR 20047009750A KR 100884685 B1 KR100884685 B1 KR 100884685B1
- Authority
- KR
- South Korea
- Prior art keywords
- purin
- fast
- amine
- active ingredient
- fludara
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (12)
- 플루다라 중의 오염물질들이 하기의 분율 (하기의 모든 분율은 중량 기준임)을 초과하지 않는 것을 특징으로 하는, 락토오스 일수화물, 콜로이드성 이산화규소, 미세결정질 셀룰로오스 (아비셀), 크로스카라멜로스-Na (나트륨 카르복시메틸 셀룰로오스) 및 스테아르산 마그네슘과 함께 순도가 99.19%를 초과하는 활성 성분 플루다라를 1 내지 100 mg 포함하는 신속-방출 정제 제제:2-플루오로-9-(β-D-아라비노푸라노실)-9H-푸린-6-아민 0.02%,6-아미노-9(5-O-포스포노-β-D-아라비노푸라노실)-9H-푸린-2-올 0.12%,2-플루오로-9H-푸린-6-아민 0.02%,6-아미노-9H-푸린-2-올 0.02%,2-플루오로-9-(5-O-포스포노-β-D-리보푸라노실)-9H-푸린-6-아민 0.05%,9-(3,5-O-디포스포노-β-D-아라비노푸라노실)-2-플루오로-9H-푸린-6-아민 0.1%,9-(2,5-O-디포스포노-β-D-아라비노푸라노실)-2-플루오로-9H-푸린-6-아민 0.1%,2-플루오로-9-(5-O-포스포노-β-D-아라비노푸라노실)-9H-푸린-6-아민 0.02%,2-에톡시-9-(5-O-포스포노-β-D-아라비노푸라노실)-9H-푸린-6-아민 0.06%,2-(6-아미노-9H-푸린-2-일)-9-(5-O-포스포노-β-D-아라비노푸라노실)-9H-푸린-6-아민 및 O,O'-비스[2-(6-아미노-2-플루오로-9H-푸린-9-일)-5-데옥시-α-D-아라비노푸라노스-5-일]-포스페이트 0.02%,9-(2-클로로-2-데옥시-5-포스포노-β-D-아라비노푸라노실)-2-플루오로-9H-푸린-6-아민 0.1% 및9-(2,5-안히드로-β-D-아라비노푸라노실)-2-플루오로-9H-푸린-6-아민 0.1%.
- 제1항에 있어서, 락토오스 일수화물 50 내지 100 mg, 콜로이드성 이산화규소 0.1 내지 5 mg, 미세결정질 셀룰로오스 (아비셀) 40 내지 100 mg, 크로스카라멜로스-Na (나트륨 카르복시메틸 셀룰로오스) 1 내지 10 mg 및 스테아르산 마그네슘 0.5 내지 10 mg과 함께 순도가 99.19%를 초과하는 활성 성분 플루다라를 1 내지 70 mg 포함하는 신속-방출 정제 제제.
- 제1항에 있어서, 락토오스 일수화물 60 내지 90 mg, 콜로이드성 이산화규소 0.5 내지 1 mg, 미세결정질 셀룰로오스 (아비셀) 50 내지 90 mg, 크로스카라멜로스-Na (나트륨 카르복시메틸 셀룰로오스) 1.5 내지 5 mg 및 스테아르산 마그네슘 1 내지 3 mg과 함께 순도가 99.19%를 초과하는 활성 성분 플루다라를 1 내지 50 mg 포함하는 신속-방출 정제 제제.
- 제1항에 있어서, 락토오스 일수화물 74.75 mg, 콜로이드성 이산화규소 0.75 mg, 미세결정질 셀룰로오스 (아비셀) 60.00 mg, 크로스카라멜로스-Na (나트륨 카르복시메틸 셀룰로오스) 3.00 mg 및 스테아르산 마그네슘 1.5 내지 2.00 mg과 함께 순도가 99.19%를 초과하는 활성 성분 플루다라를 10 mg 포함하는 신속-방출 정제 제제.
- 제1항에 있어서, 순도가 99.37%를 초과하는 활성 성분 플루다라를 포함하는 신속-방출 정제 제제.
- 제1항에 있어서, 순도가 99.57%를 초과하는 활성 성분 플루다라를 포함하는 신속-방출 정제 제제.
- 제1항에 있어서, 순도가 99.80%를 초과하는 활성 성분 플루다라를 포함하는 신속-방출 정제 제제.
- 제1항에 있어서, 순도가 99.85%를 초과하는 활성 성분 플루다라를 포함하는 신속-방출 정제 제제.
- 제1항에 있어서, 정제 코어가 히드록시프로필 메틸 셀룰로오스 1 내지 5 mg, 탈크 0.1 내지 1 mg, 이산화티탄 0.1 내지 5 mg, 산화철 황색 안료 0.01 내지 0.1 mg 및 산화철 적색 안료 0.01 내지 0.1 mg을 포함하는 코팅에 의해 싸이는 신속-방출 정제 제제.
- 제1항에 있어서, 히드록시프로필 메틸 셀룰로오스 1 내지 3 mg, 탈크 0.1 내지 0.8 mg, 이산화티탄 0.1 내지 2 mg, 산화철 황색 안료 0.01 내지 0.05 mg 및 산화철 적색 안료 0.01 내지 0.05 mg을 포함하는 코팅에 의해 싸이는 신속-방출 정제 제제.
- 제1항에 있어서, 히드록시프로필 메틸 셀룰로오스 2.250 mg, 탈크 0.450 mg, 이산화티탄 1.187 mg, 산화철 황색 안료 0.036 mg 및 산화철 적색 안료 0.036 mg을 포함하는 코팅에 의해 싸이는 신속-방출 정제 제제.
- 제1항 내지 제11항 중 어느 한 항에 있어서, 암을 치료하기 위한 정제 제제.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10164510.4 | 2001-12-20 | ||
DE10164510A DE10164510A1 (de) | 2001-12-20 | 2001-12-20 | Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes |
PCT/EP2002/013252 WO2003053418A1 (de) | 2001-12-20 | 2002-11-25 | Orale fludara reinst formulierung mit schneller freisetzung des wirkstoffes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040073501A KR20040073501A (ko) | 2004-08-19 |
KR100884685B1 true KR100884685B1 (ko) | 2009-02-18 |
Family
ID=7711168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047009750A KR100884685B1 (ko) | 2001-12-20 | 2002-11-25 | 신속 방출 활성 물질을 함유하는 초순도 플루다라 경구제제 |
Country Status (30)
Country | Link |
---|---|
US (1) | US7148207B2 (ko) |
EP (1) | EP1455760B1 (ko) |
JP (2) | JP2005519043A (ko) |
KR (1) | KR100884685B1 (ko) |
CN (1) | CN1306929C (ko) |
AR (1) | AR037965A1 (ko) |
AT (1) | ATE303797T1 (ko) |
AU (1) | AU2002349043B2 (ko) |
BR (1) | BR0215265A (ko) |
CA (1) | CA2471396A1 (ko) |
DE (2) | DE10164510A1 (ko) |
DK (1) | DK1455760T3 (ko) |
EC (1) | ECSP045185A (ko) |
ES (1) | ES2248624T3 (ko) |
HK (1) | HK1077741A1 (ko) |
HR (1) | HRP20040648B1 (ko) |
IL (2) | IL162555A0 (ko) |
JO (1) | JO2363B1 (ko) |
MX (1) | MXPA04006005A (ko) |
NO (1) | NO20043063L (ko) |
NZ (1) | NZ533701A (ko) |
PE (1) | PE20030639A1 (ko) |
RS (1) | RS50398B (ko) |
RU (1) | RU2318496C2 (ko) |
SA (1) | SA03240091B1 (ko) |
TW (1) | TWI255187B (ko) |
UA (1) | UA78741C2 (ko) |
UY (1) | UY27596A1 (ko) |
WO (1) | WO2003053418A1 (ko) |
ZA (1) | ZA200405735B (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010133629A1 (en) * | 2009-05-19 | 2010-11-25 | Grindeks, A Joint Stock Company | Stable pharmaceutical composition of fludarabine phosphate |
US20120010216A1 (en) * | 2010-07-06 | 2012-01-12 | Brown Arthur M | Pharmaceutical compositions containing vanoxerine |
EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
CN101947208B (zh) * | 2010-10-09 | 2012-05-23 | 江苏奥赛康药业股份有限公司 | 一种供注射用的磷酸氟达拉滨组合物及其制备方法 |
CN102091046B (zh) * | 2011-02-12 | 2012-07-18 | 海南锦瑞制药股份有限公司 | 一种磷酸氟达拉滨冻干粉针剂及其制备方法 |
EP3342778B1 (en) * | 2015-08-28 | 2022-01-12 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Crystal form of fludarabine phosphat, preparation method therefor, and application thereof |
CN111423458A (zh) * | 2020-04-29 | 2020-07-17 | 东南大学 | 磷酸氟达拉滨杂质h对照品的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2124901A (en) * | 1982-07-08 | 1984-02-29 | Yamasa Shoyu Kk | Enhancer of anti-tumor effect |
US6174873B1 (en) | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3903297A (en) * | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
US4210745A (en) * | 1978-01-04 | 1980-07-01 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine |
US4188378A (en) * | 1978-01-04 | 1980-02-12 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine |
US4357324A (en) * | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
US5110919A (en) * | 1989-12-04 | 1992-05-05 | Ash Stevens, Inc. | Process for the preparation of 2-amino-9-(2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl) adenine and novel intermediates |
FR2701027B1 (fr) * | 1993-02-01 | 1997-07-18 | Warner Lambert Co | Procede de synthese ameliore du 9-(beta-d-arabinofuranosyl)adenine 5'-phosphate. |
DE19543052A1 (de) | 1995-11-06 | 1997-05-07 | Schering Ag | Verfahren zur Herstellung und Reinigung von Fludarabin-Phosphat und die Verwendung von sauren Ionenaustauschern im Verfahren |
DE69713948D1 (de) * | 1996-04-23 | 2002-08-22 | Janssen Pharmaceutica Nv | Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid |
CA2210600A1 (en) * | 1996-07-17 | 1998-01-17 | Takashi Houkan | Inhibitor of tumor metastasis or recurrence |
US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
HU226997B1 (en) * | 1997-12-11 | 2010-04-28 | Alcafleu Man Gmbh & Co Kg | Method for producing lithium, sodium, potassium, calcium and magnesium salts of fludarabin phosphate purification method for producing fludarabin phosphate and fludarabin phosphate which is at least 99,5% pure |
CA2328703C (en) | 1998-06-11 | 2007-10-30 | Pharmacia & Upjohn Company | Delavirdine tablet formulation |
AU6646700A (en) | 1999-08-20 | 2001-03-19 | Scripps Research Institute, The | Formation of heterocycles |
ES2240209T3 (es) | 1999-12-08 | 2005-10-16 | Pharmacia Corporation | Composiciones de eplerenona nanoparticulada. |
US20020131988A1 (en) | 1999-12-16 | 2002-09-19 | Foster Todd P. | Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
AU1756001A (en) * | 1999-12-16 | 2001-06-25 | Pharmacia & Upjohn Company | Implant composition containing melengestrol acetate and trenbolone acetate |
US6399591B1 (en) * | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
-
2001
- 2001-12-20 DE DE10164510A patent/DE10164510A1/de not_active Ceased
-
2002
- 2002-11-25 KR KR1020047009750A patent/KR100884685B1/ko active IP Right Grant
- 2002-11-25 CA CA002471396A patent/CA2471396A1/en not_active Abandoned
- 2002-11-25 MX MXPA04006005A patent/MXPA04006005A/es active IP Right Grant
- 2002-11-25 DE DE50204203T patent/DE50204203D1/de not_active Expired - Lifetime
- 2002-11-25 WO PCT/EP2002/013252 patent/WO2003053418A1/de active IP Right Grant
- 2002-11-25 BR BR0215265-7A patent/BR0215265A/pt not_active Application Discontinuation
- 2002-11-25 UA UA20040705884A patent/UA78741C2/uk unknown
- 2002-11-25 ES ES02781328T patent/ES2248624T3/es not_active Expired - Lifetime
- 2002-11-25 JP JP2003554177A patent/JP2005519043A/ja active Pending
- 2002-11-25 RU RU2004122479/15A patent/RU2318496C2/ru not_active IP Right Cessation
- 2002-11-25 CN CNB028279034A patent/CN1306929C/zh not_active Expired - Fee Related
- 2002-11-25 AT AT02781328T patent/ATE303797T1/de active
- 2002-11-25 AU AU2002349043A patent/AU2002349043B2/en not_active Ceased
- 2002-11-25 RS YUP-533/04A patent/RS50398B/sr unknown
- 2002-11-25 DK DK02781328T patent/DK1455760T3/da active
- 2002-11-25 EP EP02781328A patent/EP1455760B1/de not_active Expired - Lifetime
- 2002-11-25 NZ NZ533701A patent/NZ533701A/xx not_active IP Right Cessation
- 2002-11-25 IL IL16255502A patent/IL162555A0/xx active IP Right Grant
- 2002-12-10 JO JO2002123A patent/JO2363B1/en active
- 2002-12-19 UY UY27596A patent/UY27596A1/es not_active Application Discontinuation
- 2002-12-20 US US10/324,141 patent/US7148207B2/en not_active Expired - Fee Related
- 2002-12-20 TW TW091136814A patent/TWI255187B/zh not_active IP Right Cessation
- 2002-12-20 AR ARP020105054A patent/AR037965A1/es not_active Application Discontinuation
-
2003
- 2003-01-06 PE PE2003000017A patent/PE20030639A1/es not_active Application Discontinuation
- 2003-04-27 SA SA03240091A patent/SA03240091B1/ar unknown
-
2004
- 2004-06-16 IL IL162555A patent/IL162555A/en not_active IP Right Cessation
- 2004-07-12 EC EC2004005185A patent/ECSP045185A/es unknown
- 2004-07-15 HR HR20040648 patent/HRP20040648B1/xx not_active IP Right Cessation
- 2004-07-19 NO NO20043063A patent/NO20043063L/no not_active Application Discontinuation
- 2004-07-19 ZA ZA2004/05735A patent/ZA200405735B/en unknown
-
2005
- 2005-11-03 HK HK05109796A patent/HK1077741A1/xx not_active IP Right Cessation
- 2005-12-28 JP JP2005379628A patent/JP2006137771A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2124901A (en) * | 1982-07-08 | 1984-02-29 | Yamasa Shoyu Kk | Enhancer of anti-tumor effect |
US6174873B1 (en) | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2000763C (en) | Dispersable formulation | |
EP2068835A2 (en) | Imatinib compositions | |
KR100884685B1 (ko) | 신속 방출 활성 물질을 함유하는 초순도 플루다라 경구제제 | |
KR20150015500A (ko) | 엔테카비어의 약제학적 조성물 및 제조 방법 | |
EP0500851B1 (en) | Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure | |
JP2000191516A (ja) | 経口固形組成物 | |
JPH10511103A (ja) | エナラプリル塩の安定固形製剤及びその製造のための方法 | |
WO2006134610A1 (en) | Efavirenz pharmaceutical composition having enhanced dissolution profile | |
ES2588011T3 (es) | Composiciones de S-adenosilmetionina orales | |
JP4387192B2 (ja) | S−アデノシルメチオニンを含む錠剤の調製方法 | |
ES2279715B1 (es) | Formulacion oral de olanzapina. | |
KR20100090138A (ko) | 경구용 결핵의 치료용 또는 예방용 고형 제형 | |
JP2009091362A (ja) | 高含量ファムシクロビル錠剤 | |
JPH026543A (ja) | アルギネートとポリアクリレートの混合物及びその使用 | |
EP2117534B1 (en) | A pharmaceutical composition with atorvastatin active ingredient | |
JP2009538905A (ja) | 感湿性薬物を含んで成る安定性製剤及びその製造方法 | |
ES2265538T3 (es) | Composicion farmaceutica solida que contiene clorhidrato de tilidina. | |
JP4824224B2 (ja) | 糖衣製剤 | |
JPH06192093A (ja) | 医薬組成物製造のための補助剤混合物と非固体活性化合物からの吸着体 | |
WO2023128898A1 (en) | Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients | |
JP2003095939A (ja) | 安定なプラバスタチンナトリウム錠 | |
PL203451B1 (pl) | Doustny preparat Fludara o najwy zszym stopniu czysto sci o szybkim uwalnianiu substancji czynnej | |
JP2002226371A (ja) | プラバスタチンナトリウムの錠剤 | |
JP2009542806A (ja) | 感湿性薬物及び第2薬物の組合せを含んで成る安定製剤及びその製造方法 | |
JPS60190724A (ja) | 経口投与製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130117 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140121 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150119 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160119 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170119 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180118 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190116 Year of fee payment: 11 |